McCulloch Kevin sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $12.49 for −$312k on Nov 5, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
See Remarks
See Remarks
Filed Nov 6, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$312,215Shares × reported price
Shares traded
25,000Common Stock
Price per share
$12.49Reported price. Read footnotes for ranges.
% of reported position traded
1.58%This security and ownership context
Holdings after
1,559,208Direct
Trade date
Nov 5, 2026Sell
Filed
Nov 6, 2026, 4:32 PM ET1-day reporting delay
Accession
0001867096-26-000119Code S · Transaction 394919
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 1,584,208 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

XERS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
XERS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −34%1w ago −29%1d ago −30%
Returns since7d +9.6%30d90d180d1y

Footnotes in full

F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.380 to $12.510, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.